Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients.It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
